Last updated on July 2019

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_


Brief description of study

The name of this trial is MissionAD2. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for end points for the studies E2609-G000-301 (NCT02956486) and E2609-G000-302 (NCT03036280) will be pooled for a combined total of 1900 participants.

Clinical Study Identifier: NCT03036280

Find a site near you

Start Over

Eisai Trial Site 4

Bunkyo-ku, Japan
0.81miles
  Connect »

Eisai Trial Site 1

Chuo-ku, Japan
2.81miles
  Connect »

Eisai Trial Site 2

Shinjuku-ku, Japan
2.9miles
  Connect »

Eisai Trial Site 1

Shinjuku-ku, Japan
2.9miles
  Connect »

Eisai Trial Site 1

Minato-ku, Japan
3.45miles
  Connect »

Eisai Trial Site 1

Shibuya-ku, Japan
4.2miles
  Connect »

Eisai Trial Site 1

Koto-ku, Japan
5.4miles
  Connect »

Eisai Trial Site 1

Katsushika-ku, Japan
5.87miles
  Connect »

Eisai Trial Site 1

Nerima-Ku, Japan
5.95miles
  Connect »

Eisai Trial Site 1

Shinagawa-ku, Japan
6.94miles
  Connect »

Eisai Trial Site 2

Shinagawa-ku, Japan
6.94miles
  Connect »

Eisai Trial Site 1

Nerima-ku, Japan
8.03miles
  Connect »

Eisai Trial Site 1

Ota-ku, Japan
8.59miles
  Connect »

Eisai Trial Site 2

Ota-ku, Japan
8.7miles
  Connect »

Eisai Trial Site 1

Urayasu, Japan
9.22miles
  Connect »